China Biopharma signs marketing agreement with Beijing Keyuan

According to the agreement, China Biopharma will distribute pharmaceutical products made by international companies including human vaccines in China using its sales network and distribution logistics.

In order to effectively conduct its business operation and change from its passive marketing approach in China, the company has shifted its market strategy to working more closely with new pharmaceutical products from global leading pharmaceutical companies in addition to local products.

Qiumeng Wang, COO of China Biopharma, said: “We are very excited about the agreement we have reached with Beijing Keyuan Xinhai Pharmaceutical. It will significantly improve our current operation situation.”